The increasing worldwide prevalence of obesity is creating a growing demand for effective treatments. One possible option is rimonabant. Cochrane Review Authors analysed data from four randomized controlled studies in which people were either given 20 mg rimonabant, 5 mg rimonabant or a placebo. At the same time they all followed a low calorie diet. Each of the trials ran for 1 year.
Over the year, people taking 20 mg rimonabant lost 4.9 kg more than those given the placebo. Those taking 5 mg only lost 1.3 kg more when compared with placebo.
Taking the higher dose of 20 mg rimonabant did, however, cause significantly more adverse effects, which may account for the fact that 40% of people overall dropped out of the trials early
“Even modest amounts of weight loss may be beneficial, though drug therapy in obesity should always be considered in connection with non-pharmacological interventions,” says lead author, Cintia Curioni who works at the Instituto de Medicina Social, in Rio de Janeiro, Brazil.
The Authors also comment that preventing non-obese individuals becoming obese, and using non-pharmacological interventions should remain the cornerstones of obesity therapy. Better quality studies with longer follow-up and outcomes which are important for patients, such as health-related quality of life, are needed to establish the place of rimonabant in the treatment of obesity.
Polly Young | alfa
Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn
On track to heal leukaemia
18.01.2017 | Universitätsspital Bern
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
19.01.2017 | Earth Sciences
19.01.2017 | Life Sciences
19.01.2017 | Physics and Astronomy